Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity
Amy C Sherman, Michaël Desjardins, Chi‐An Cheng, Bruce Bausk, Natalie Izaguirre, Guohai Zhou, Jonathan Krauß, Nicole V. Tolan, David R. Walt, Robert J. Soiffer, Vincent T. Ho, Nicolas C. Issa, Lindsey R. Baden
Abstract
The severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine-induced humoral response and reactogenicity profile are described in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Findings showed that 75.0% (by Simoa assay) or 80.0% (by Roche assay) of the HSCT cohort had a positive antibody response on series completion, compared with 100% in the healthy cohort.
Topics & Concepts
ReactogenicityMedicineImmunogenicityHematopoietic stem cell transplantationImmunologyStem cellHaematopoiesisCohortCoronavirusVirologyAntibodyTransplantationInternal medicineCoronavirus disease 2019 (COVID-19)BiologyDiseaseGeneticsInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 Impact on Reproduction